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Children with acute lymphoblastic leuke-
mia (ALL) are treated with combination
chemotherapy with an expected cure rate
of 80%. This success stands as one of
the crowning achievements of modern
cancer therapy. Unfortunately, ALL is a
common disease, and much more work
needs to be done to achieve cures for 
all children. Furthermore, a small pro-
portion of children treated for ALL devel-
op secondary acute myelogenous
leukemia (AML), which can be a fatal
event. Thus, a major goal in ALL is to
accurately diagnose patients who are at
risk for either relapse or secondary
leukemias, and to develop alternative
therapies for these patients. This chal-
lenge has been undertaken by three
recent gene expression profiling studies
of pediatric ALL (Armstrong et al., 2001;
Ferrando et al., 2002; Yeoh et al., 2002
[this issue of Cancer Cell]).
Recurrent chromosomal transloca-
tions and imbalances are the defining
molecular features of ALL, and these
oncogenic events identify clinically dis-
tinct subgroups of patients. In B cell ALL
(B-ALL), translocations often fuse two
genes, resulting in the translation of a
fusion oncoprotein (Ferrando and Look,
2000). The t(12;21)/TEL-AML1 and
t(1;19)/E2A-PBX1 translocations define
patients with relatively good treatment
outcome, especially following dose 
intensified chemotherapy. Patients with
t(9;22)/BCR-ABL or t(4;11)/MLL-AF4
translocations have a relatively poor
prognosis, but hematopoietic stem cell
transplantation from a HLA-matched sib-
ling donor has been shown to be benefi-
cial for patients with BCR-ABL transloca-
tions (Arico et al., 2000). A hyperdiploid
chromosomal content (>50 chromo-
somes) defines a favorable prognostic
group in B-ALL, but the molecular corre-
lates of this chromosomal imbalance
have been obscure. T cell ALL (T-ALL) is
characterized by recurrent, but infre-
quent, chromosomal translocations that
result in overexpression of transcription
factors that are presumed to deregulate
early thymocyte development, resulting
in leukemia (Ferrando and Look, 2000).
As in B-ALL, these translocations define
patient subsets with different clinical out-
comes (Ferrando and Look, 2000).
A primary goal of the recent gene
expression profiling studies was, there-
fore, to identify which genes are exp-
ressed in association with each chromo-
somal abnormality. Interestingly, this was
an exceedingly easy task. Each chromo-
somal abnormality in B-ALL had a char-
acteristic gene expression signature
composed of a large number of genes.
Indeed, the leukemia subtypes were
found to be as distinct in gene expression
as are various types of epithelial cancer
(Ramaswamy et al., 2001; Su et al.,
2001).The differentially expressed genes
could be fashioned into predictors of the
leukemia subtypes that functioned with
extremely high accuracy. Importantly, in
the largest study (Yeoh et al., 2002), the
leukemia subtype predictor was devel-
oped on a training set of ALL cases and
was tested on an independent set of
cases in which it performed with 96%
accuracy. Given the large number of sta-
tistical associations that are made during
the analysis of gene expression profiling
data, the use of an independent valida-
tion set is an exceedingly important ana-
lytical method that avoids the danger of
overfitting statistical models to the data.
As in most large-scale gene expres-
sion profiling studies, unexpected obser-
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The molecular diagnosis of human cancer will hasten the development of treatments tailored to the abnormalities present
in each patient’s tumor cells. Recent gene expression profiling studies of pediatric acute lymphoblastic leukemia (ALL)
suggest that the molecular diagnosis of these diseases is right around the corner.
Figure 1. Molecular subtypes of acute lym-
phoblastic leukemia (ALL)
B-cell ALLs (B-ALL) are derived from precursor
B cells in the bone marrow. The variety of
chromosomal translocations and abnormali-
ties of chromosome number that cause
malignant transformation are shown. Gene
expression profiles of B-ALLs define gene
expression signatures of each of these onco-
genic events. T cell ALLs (T-ALLs) are derived
from precursor T cells in the thymus.
Infrequent but recurrent translocations lead
to the overexpression of the transcription
factors LYL1, HOX11, HOX11L2, and TAL1.
Overexpression of these genes in the ab-
sence of translocation (indicated by the 
+ sign) occurs in more cases of T-ALL.
Molecular subtypes of T-ALL defined by
oncogene overexpression are characterized
by gene expression signatures that suggest
that the T-ALLs are blocked at discrete
stages in normal thymocyte differentiation,
as indicated.
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vations were plentiful. 70% of the genes
that were found to be preferentially
expressed in the hyperdiploid leukemia
subtype are encoded on chromosomes
21 and X (Yeoh et al., 2002).This unusual
result is not apparently explained by
numerical abnormalities of these chro-
mosomes, but instead may indicate a
regulatory mechanism that operates at
the level of whole chromosomes. Another
unexpected observation was that 14 B-
ALL cases that lacked the recurrent B-
ALL chromosomal abnormalities none-
theless shared a large gene expression
signature that distinguished them from
the other leukemia subtypes (Yeoh et al.,
2002). These cases constitute a novel
leukemia subtype for which the onco-
genic event is currently unknown. Finally,
20% of the B-ALL cases could not be
sorted into any of the leukemia subtypes
by gene expression (Yeoh et al., 2002).
Since some chromosomal translocations
in B-ALL are exceedingly infrequent, it
may be necessary to profile many more
ALLs, possibly thousands, to define rare
leukemia subtypes to which these orphan
cases belong.
In contrast to the high frequency of
recurrent translocations in B-ALL, only
30% of T-ALL cases have chromosomal
translocations (Ferrando and Look,
2000). Gene expression profiling of T-ALL
provided a fascinating explanation for this
disparity; namely, that the oncogenes
HOX11, TAL1, and LYL1 that are involved
in T-ALL translocations can also be over-
expressed by other means in cases lack-
ing translocations (Ferrando et al., 2002).
The overexpression of each T-ALL onco-
gene was associated with a characteris-
tic gene expression signature, and these
signature genes were used to organize
all T-ALL cases into clusters with related
gene expression. In this way, some cases
that did not overexpress a particular
oncogene were nevertheless grouped
with cases that did, based on similar
expression of other genes. Intriguingly,
the HOX11 cluster included some cases
that overexpressed a highly related gene,
HOX11L2, instead of HOX11. Impor-
tantly, other oncogenic events, such as
deletion of the p16/ARF locus, were
found to be selectively present in certain
T-ALL subtypes defined in this manner,
suggesting that these subtypes represent
pathogenetically distinct diseases.
Deregulation of oncogenes appears
to be central to the molecular diagnosis of
ALL, but what is the mechanism by which
these oncogenes give rise to distinct
leukemia subtypes? The clearest answer
to this question comes from the study of
T-ALL in which the leukemia subtypes
defined by oncogene overexpression cor-
responded to different stages in normal
thymocyte differentiation (Ferrando et al.,
2002), presumably indicating that the
oncogenes act by blocking differentiation
(Figure 1). The cell of origin of a tumor
can be important in determining the clini-
cal outcome of patients, as shown for dif-
fuse large B cell lymphoma (Alizadeh et
al., 2000), since stages of normal differ-
entiation vary in proliferative potential
and propensity for apoptosis. Indeed, the
T-ALL subtypes were found to define clin-
ically distinct patient subsets (Ferrando et
al., 2002). The association of the B-ALL
subtypes with normal B cell differentia-
tion is less clear (Yeoh et al., 2002), but
those cases with the MLL-AF4 transloca-
tion most resembled very early B cell pre-
cursors that coexpress both B cell and
myeloid markers (Armstrong et al., 2001).
Gene expression profiling of well-defined
subsets of human B cell precursors will
be required to carefully assess the rela-
tionship between B-ALL subtypes and
normal B cell development.
From the clinical standpoint, DNA
microarrays represent a viable alternative
to conventional karyotyping and fluores-
cence in situ hybridization for the diagno-
sis of leukemia subtypes, especially
since gene expression profiles can identi-
fy cases with translocations that are cyto-
genetically invisible (Yeoh et al., 2002). In
B-ALL, gene expression profiles may be
able not only to classify patients into
leukemic subtypes, but also to predict
treatment failure (Yeoh et al., 2002).
Interestingly, gene expression-based
predictors of relapse only worked among
cases that shared a common chromoso-
mal abnormality (Yeoh et al., 2002). This
result suggests that the leukemia sub-
types differ profoundly in oncogenic
mechanisms and utilization of signaling
pathways, and therefore have distinct
mechanisms to resist chemotherapy. An
intriguing, but puzzling, result was that
development of secondary AML could
also be predicted from gene expression
in the B-ALL blasts, even though the AML
and B-ALL cells are thought to arise from
different precursor cells (Yeoh et al.,
2002). Conceivably, a subset of B-ALL
patients could have an underlying molec-
ular lesion in a hematopoietic stem cell
that predisposes them to secondary AML
and is reflected in the gene expression
profiles of their B-ALL blasts.
An important caveat is that the pre-
dictors of patient survival presented in
these gene expression profiling papers
will need to be validated in an indepen-
dent set of cases. Ideally, DNA microar-
ray technology will be included in any
new prospective clinical trial in pediatric
ALL and, for that matter, in all cancer tri-
als. It will be interesting to compare the
gene expression profiles of adult and
pediatric ALLs, since the same translo-
cations are recurrent in adult ALL, yet
adults fail therapy more often. Now that
the molecular diagnosis of ALL is well
underway, the burden will shift toward
identifying novel therapies that target
the specific regulatory pathways active
in each leukemia subtype, leading, we
hope, to the eradication of this disease.
Louis M. Staudt
Metabolism Branch
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